Crossmark

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

Crossref DOI link: https://doi.org/10.1038/s41586-020-2901-9

Published Online: 2020-10-28

Published Print: 2021-01-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Han, Yuling https://orcid.org/0000-0002-6805-4094
Duan, Xiaohua

Yang, Liuliu

Nilsson-Payant, Benjamin E. https://orcid.org/0000-0003-2661-7837
Wang, Pengfei

Duan, Fuyu

Tang, Xuming

Yaron, Tomer M. https://orcid.org/0000-0001-6574-7314
Zhang, Tuo https://orcid.org/0000-0001-5396-918X
Uhl, Skyler

Bram, Yaron

Richardson, Chanel

Zhu, Jiajun

Zhao, Zeping

Redmond, David

Houghton, Sean

Nguyen, Duc-Huy T.

Xu, Dong

Wang, Xing https://orcid.org/0000-0003-0106-202X
Jessurun, Jose https://orcid.org/0000-0002-1692-9880
Borczuk, Alain

Huang, Yaoxing https://orcid.org/0000-0001-6270-1644
Johnson, Jared L. https://orcid.org/0000-0003-1802-6527
Liu, Yuru

Xiang, Jenny

Wang, Hui

Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
tenOever, Benjamin R. https://orcid.org/0000-0003-0324-3078
Ho, David D. https://orcid.org/0000-0003-1627-149X
Pan, Fong Cheng https://orcid.org/0000-0002-9393-6574
Evans, Todd https://orcid.org/0000-0002-7148-9849
Chen, Huanhuan Joyce

Schwartz, Robert E.

Chen, Shuibing https://orcid.org/0000-0002-6294-5187
License Information

Text and Data Mining valid from 2020-10-28

Version of Record valid from 2020-10-28
More Information

Article History

Received: 5 May 2020

Accepted: 21 October 2020

First Online: 28 October 2020

Change Date: 29 May 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41586-024-07593-9

Competing interests

: R.E.S. is on the scientific advisory board of Miromatrix Inc. and is a consultant and speaker for Alnylam Inc. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals. L.C.C. is an inventor on patents (pending) for Combination Therapy for PI3K-associated Disease or Disorder, and The Identification of Therapeutic Interventions to Improve Response to PI3K Inhibitors for Cancer Treatment. L.C.C. is a co-founder and shareholder in Faeth Therapeutics. T.M.Y. is a stockholder and on the board of directors of DESTROKE, Inc., an early stage start-up developing mobile technology for automated clinical stroke detection. The other authors declare no competing interests.

Free to read: This content has been made available to all.

Updates are available Correction dated 2024-05-29

Click to view Correction: https://doi.org/10.1038/s41586-024-07593-9